Quick Answer
Omada Health, Inc. reported R&D Expense of $40.68 million for fiscal year 2025.
Omada Health, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $40.68M | +13.3% |
| 2024 | $35.92M | +6.5% |
| 2023 | $33.74M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.30M | +16.4% | +2.8% |
| June 30, 2025 | $10.02M | +11.5% | +13.3% |
| September 30, 2024 | $8.85M | — | -1.5% |
| June 30, 2024 | $8.99M | — | — |
- Omada Health, Inc. showed an increase of +13.3% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Omada Health, Inc.’s r&d expense has grown by 20.6% (from $33.74 million to $40.68 million).
- The most recent figure is from Omada Health, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: